{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:17:21Z","timestamp":1787829441246,"version":"build-2784847793"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2024-00512384"],"award-info":[{"award-number":["RS-2024-00512384"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-34325-4","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T17:44:47Z","timestamp":1767980687000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world outcomes of ranibizumab biosimilars in various retinal diseases: a Korean multi-center experience\u2014ROSE Korea Study"],"prefix":"10.1038","volume":"16","author":[{"given":"Jae Ryong","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Un Chul","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Seungkyu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Jin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Chul","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areum","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hui","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Sagong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Joon","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"International Retina Biosimilar Study Group (Inter BIOS Group)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baruch D.","family":"Kuppermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Loewenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bandello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl D.","family":"Regillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Vazquez-Alfageme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikulaa","family":"Parachuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seemantini","family":"Ayachit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alay","family":"Banker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kourous A.","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshad M.","family":"Khanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter K.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobha","family":"Sivaprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Querques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eeng\u00fcl","family":"\u00d6zdek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kodjikian","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alper","family":"Bilgic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Lanzetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline R.","family":"Baumal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Holekemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiji","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Tufail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Yannuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Corradetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitaranjan","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debdulal","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Rachitskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tunde","family":"Peto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian W. M.","family":"Wintergerst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Sarao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Parolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil Ghasemi","family":"Falavarjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan Dong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana V.","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearse A.","family":"Keane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayanth","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Eichenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilraj S.","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"March","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Spitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Zinkernagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Ueda-Consolvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichiro","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"34325_CR1","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12886-020-01554-2","volume":"20","author":"RP Finger","year":"2020","unstructured":"Finger, R. P. et al. Anti-vascular endothelial growth factor in neovascular age-related macular degeneration\u2014a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems. BMC Ophthalmol. 20, 294 (2020).","journal-title":"BMC Ophthalmol."},{"key":"34325_CR2","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"R Waring","year":"2006","unstructured":"Waring, R. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1419\u20131431 (2006).","journal-title":"N. Engl. J. Med."},{"key":"34325_CR3","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown, D. M. et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1432\u20131444 (2006).","journal-title":"N. Engl. J. Med."},{"key":"34325_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown, D. M. et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 116, 57-65.e5 (2009).","journal-title":"Ophthalmology"},{"key":"34325_CR5","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/j.ophtha.2012.05.017","volume":"119","author":"R Varma","year":"2012","unstructured":"Varma, R. et al. Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. Ophthalmology 119, 2108\u20132118 (2012).","journal-title":"Ophthalmology"},{"key":"34325_CR6","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.ophtha.2013.02.034","volume":"120","author":"DM Brown","year":"2013","unstructured":"Brown, D. M. et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 120, 2013\u20132022 (2013).","journal-title":"Ophthalmology"},{"key":"34325_CR7","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.4103\/ijo.IJO_1866_19","volume":"68","author":"A Kelkar","year":"2020","unstructured":"Kelkar, A. et al. Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in Indian patients with retinal vein occlusion, age-related macular degeneration, and diabetic macular edema. Indian J. Ophthalmol. 68, 2143\u20132147 (2020).","journal-title":"Indian J. Ophthalmol."},{"key":"34325_CR8","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s40123-022-00488-w","volume":"11","author":"SM Hariprasad","year":"2022","unstructured":"Hariprasad, S. M. et al. An introduction to biosimilars for the treatment of retinal diseases: a narrative review. Ophthalmol. Ther. 11, 959\u2013982 (2022).","journal-title":"Ophthalmol. Ther."},{"key":"34325_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1001\/jamaophthalmol.2022.5403","volume":"141","author":"NM Bressler","year":"2023","unstructured":"Bressler, N. M. et al. Immunogenicity with ranibizumab biosimilar SB11 (Byooviz) and reference product lucentis and association with efficacy, safety, and pharmacokinetics: a post hoc analysis of a phase 3 randomized clinical trial. JAMA Ophthalmol. 141, 117\u2013127 (2023).","journal-title":"JAMA Ophthalmol."},{"key":"34325_CR10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ophtha.2021.04.031","volume":"129","author":"FG Holz","year":"2022","unstructured":"Holz, F. G. et al. Efficacy and safety of biosimilar FYB201 compared with ranibizumab in neovascular age-related macular degeneration. Ophthalmology 129, 54\u201363 (2022).","journal-title":"Ophthalmology"},{"key":"34325_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0275611","volume":"17","author":"CK Yoon","year":"2022","unstructured":"Yoon, C. K. et al. Efficacy and safety of a new ranibizumab biosimilar CKD-701 using a pro re nata treatment regimen in neovascular age-related macular degeneration: A phase 3 randomized clinical trial. PLoS ONE 17, e0275611 (2022).","journal-title":"PLoS ONE"},{"key":"34325_CR12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.oret.2024.10.001","volume":"9","author":"J Hamouz","year":"2025","unstructured":"Hamouz, J. et al. Efficacy and safety of ranibizumab biosimilar QL1205 in neovascular age-related macular degeneration. Ophthalmol. Retina 9, 343\u2013351 (2025).","journal-title":"Ophthalmol. Retina"},{"key":"34325_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ajo.2020.11.017","volume":"224","author":"A Sharma","year":"2021","unstructured":"Sharma, A. et al. Biosimilars for retinal diseases: an update. Am. J. Ophthalmol. 224, 36\u201342 (2021).","journal-title":"Am. J. Ophthalmol."},{"key":"34325_CR14","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2025.0040","author":"H Lee","year":"2025","unstructured":"Lee, H., Sharma, A. & Woo, S. J. Clinical trials of aflibercept biosimilars: a review. J. Ocul. Pharmacol. Ther. https:\/\/doi.org\/10.1089\/jop.2025.0040 (2025).","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"34325_CR15","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1136\/bjophthalmol-2021-319637","volume":"107","author":"NM Bressler","year":"2023","unstructured":"Bressler, N. M. et al. Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes. Br. J. Ophthalmol. 107, 384\u2013391 (2023).","journal-title":"Br. J. Ophthalmol."},{"key":"34325_CR16","unstructured":"Ministry of Food and Drug Safety of the Republic of Korea. Amelivu [https:\/\/nedrug.mfds.go.kr\/pbp\/CCBBB01\/getItemDetailCache?cacheSeq=202202008%26updateTs=2023-02-15%2015:44:12.247591] (Accessed 02 Sept 2025)."},{"key":"34325_CR17","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1038\/s41433-024-03284-x","volume":"38","author":"A Sharma","year":"2024","unstructured":"Sharma, A. et al. Anti-VEGF biosimilars for retinal diseases survey 2023- India (Bio-INDAS) by the International Retina Biosimilar Study Group (Inter-BIOS Group) in collaboration with the Vitreo-Retinal Society of India (VRSI). Eye 38, 3392\u20133395 (2024).","journal-title":"Eye"},{"key":"34325_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/jamaophthalmol.2020.5053","volume":"139","author":"SJ Woo","year":"2021","unstructured":"Woo, S. J. et al. Efficacy and safety of a proposed ranibizumab biosimilar product vs a reference ranibizumab product for patients with neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmol. 139, 68 (2021).","journal-title":"JAMA Ophthalmol."},{"key":"34325_CR19","first-page":"24","volume":"241","author":"S Sharma","year":"2018","unstructured":"Sharma, S., Khan, M. A. & Chaturvedi, A. Real-life clinical effectiveness of Razumab\u00ae (the world\u2019s first biosimilar of ranibizumab) in retinal vein occlusion: a subgroup analysis of the pooled retrospective RE-ENACT study. Ophthalmol. Int. J. Ophthalmol. 241, 24\u201331 (2018).","journal-title":"Ophthalmol. Int. J. Ophthalmol."},{"key":"34325_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2022.101358","volume":"25","author":"A Sharma","year":"2022","unstructured":"Sharma, A. et al. Ranizurel safety evaluation in real-world -(RaSER) study. Am. J. Ophthalmol. Case Rep. 25, 101358 (2022).","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"34325_CR21","doi-asserted-by":"publisher","DOI":"10.1177\/24741264251322213","author":"A Sharma","year":"2025","unstructured":"Sharma, A. et al. Biosimilar ranibizumab (ranieyes) safety and efficacy in the real world: BRESER study. J. Vitreoretin. Dis. https:\/\/doi.org\/10.1177\/24741264251322213 (2025).","journal-title":"J. Vitreoretin. Dis."},{"key":"34325_CR22","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1038\/s41433-024-03220-z","volume":"38","author":"T Ueda-Consolvo","year":"2024","unstructured":"Ueda-Consolvo, T. et al. Biosimilar ranibizumab (BS1) \u2013 early experience from Japan (BRIJ study). Eye 38, 3193\u20133196 (2024).","journal-title":"Eye"},{"key":"34325_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3341\/jkos.2025.66.1.27","volume":"66","author":"D Shin","year":"2025","unstructured":"Shin, D., Kim, Y. & Kim, J. H. Short-term outcomes of ranibizumab biosimilar CKD-701 treatment in macular edema secondary to retinal vein occlusion. J. Korean Ophthalmol. Soc. 66, 27\u201335 (2025).","journal-title":"J. Korean Ophthalmol. Soc."},{"key":"34325_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.21561\/jor.2024.9.2.127","volume":"9","author":"YS Yoon","year":"2024","unstructured":"Yoon, Y. S. & Kim, J. H. Short-term anatomical outcomes of switching from bevacizumab to the ranibizumab biosimilar CKD-701 in neovascular age-related macular degeneration. J. Retina 9, 127\u2013133 (2024).","journal-title":"J. Retina"},{"key":"34325_CR25","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.oret.2023.05.005","volume":"7","author":"A Loewenstein","year":"2023","unstructured":"Loewenstein, A. et al. Randomized trial of biosimilar XSB-001 versus reference ranibizumab in patients with neovascular age-related macular degeneration. Ophthalmol. Retina 7, 753\u2013761 (2023).","journal-title":"Ophthalmol. Retina"},{"key":"34325_CR26","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","volume":"117","author":"PA Campochiaro","year":"2010","unstructured":"Campochiaro, P. A. et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117, 1102-1112.e1 (2010).","journal-title":"Ophthalmology"},{"key":"34325_CR27","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.ophtha.2006.06.052","volume":"114","author":"Diabetic Retinopathy Clinical Research Network","year":"2007","unstructured":"Diabetic Retinopathy Clinical Research Network. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 114, 525\u2013536 (2007).","journal-title":"Ophthalmology"},{"key":"34325_CR28","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3341\/kjo.2018.0081","volume":"33","author":"SJ Woo","year":"2019","unstructured":"Woo, S. J., Cho, G. E. & Cho, J. H. Short-term efficacy and safety of ranibizumab for neovascular age-related macular degeneration in the real world: a post-marketing surveillance study. Korean J. Ophthalmol. KJO 33, 150\u2013166 (2019).","journal-title":"Korean J. Ophthalmol. KJO"},{"key":"34325_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244183","volume":"15","author":"FG Holz","year":"2020","unstructured":"Holz, F. G. et al. Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: Real-world outcomes from the LUMINOUS study. PLoS ONE 15, e0244183 (2020).","journal-title":"PLoS ONE"},{"key":"34325_CR30","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.2147\/OPTH.S303884","volume":"15","author":"M Sagong","year":"2021","unstructured":"Sagong, M., Woo, S. J., Lee, Y., LUMINOUSTM study investigators from South Korea. Real-World effectiveness, treatment pattern, and safety of ranibizumab in Korean patients with neovascular age-related macular degeneration: subgroup analyses from the LUMINOUS study. Clin. Ophthalmol. Auckl. NZ 15, 1995\u20132011 (2021).","journal-title":"Clin. Ophthalmol. Auckl. NZ"},{"key":"34325_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2022-001205","volume":"8","author":"A Hatamnejad","year":"2023","unstructured":"Hatamnejad, A., Dadak, R., Orr, S., Wykoff, C. & Choudhry, N. Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment. BMJ Open Ophthalmol. 8, e001205 (2023).","journal-title":"BMJ Open Ophthalmol."},{"key":"34325_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaophthalmol.2021.0640","volume":"139","author":"N Ngo Ntjam","year":"2021","unstructured":"Ngo Ntjam, N. et al. Cardiovascular adverse events with intravitreal anti-vascular endothelial growth factor drugs: a systematic review and meta-analysis of randomized clinical trials. JAMA Ophthalmol. 139, 1\u201311 (2021).","journal-title":"JAMA Ophthalmol."},{"key":"34325_CR33","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1097\/IAE.0000000000002670","volume":"40","author":"FG Holz","year":"2020","unstructured":"Holz, F. G. et al. Ranibizumab treatment in treatment-naive neovascular age-related macular degeneration: Results from luminous, a global real-world study. Retina Phila. Pa 40, 1673\u20131685 (2020).","journal-title":"Retina Phila. Pa"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34325-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34325-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34325-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T10:00:02Z","timestamp":1769767202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34325-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["34325"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-34325-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"9 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Se Joon Woo received consulting fees from Astellas, Boeringer Ingelheim, Curacle, Janssen, Novelty Nobility, Pharmabcine, Optus, Samsung Bioepis, Samil, Sometech, lecture fees from Alcon, Bayer, Navartis, Abbvie, Roche, Santen, Samil, Zeiss; grants from Samsung Bioepis, Alcon, Alteogen, Curacle, Kyowa Kirin, Novelty Nobility, Novartis, Pharmabcine, Roche, Zeiss; owns equity of RetiMark and Panolos Bioscience. Jae Hui Kim has received lecture fees from Novartis, Bayer, Roche, Astellas, Samsung Bioepis, Samil, Chong Kun Dang, Kukje, and Optus Min Sagong received consulting fees from Curacle, Janssen, Pharmabcine, Samsung Bioepis, Samil, lecture fees from Alcon, Bayer, Novartis, Abbvie, Roche, Santen, Samil, Zeiss; grants from Samsung Bioepis, Alcon, Alteogen, Curacle, Jassen, Kyowa Kirin, Novartis, Pharmabcine, Roche, and Johnson & Johnson. Ashish Sharma- Consultant and Speaker- Oculis, Novartis, Allergan, Bayer, Lupin, Intas, Ajanta and Sun Pharma Speaker fee MS Pharma, Abdi \u0130brahim \u0130la\u00e7 San. ve Tic, Samil Pharma, Roche Other authors- None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4220"}}